The researchers assessed the cardiovascular and cerebrovascular safety of ranibizumab 0.3mg and 0.5mg vs. sham with and without laser in diabetic macular edema.
Regeneron previously reported positive interim Phase 2 results which showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55%.
The data revealed "no consistent evidence of effect modification by various foods, nutrients, dietary patterns, or baseline supplement use" with multivitamin use on cardiovascular disease outcomes.
Treatment with Repatha reached its primary endpoint of reducing the need for continued apheresis at the end of the randomization period.
Migraine sufferers may face a slightly higher risk of stroke after an operation, according to research published online January 10 in The BMJ.
A metabolite produced in the digestion of red meat, eggs, and dairy products - trimethylamine N-oxide (TMAO) - is linked to an increased risk of a fatal myocardial infarction or stroke.
Betrixaban has the potential to be the first anticoagulant approved for in-hospital and extended-duration VTE in high-risk acute medically ill patients.
The risk of heart attack and stroke among patients with HIV was predicted to be nearly double that of the general population
Tranexamic acid is associated with a lower risk of bleeding than placebo for patients undergoing coronary artery surgery without increased risk of death or thrombotic complications, according to a study published online in the New England Journal of Medicine
Non-dihydropyridine calcium channel blockers and loop diuretics were associated with a lower risk of dementia independent of blood pressure variability (percent coefficient of variation [CV]) in the preceding 4 years, researchers found in a study published in Neurology.
Impaired cardiac autonomic function is associated with coronary flow reserve (CFR) in patients with type 2 diabetes, according to a study published in the June issue of Diabetes.
Research presented at Frontiers in CardioVascular Biology (FCVB) 2016 shows that a diagnosis of high cholesterol was associated with lower mortality and improved survival in four common cancers: lung, breast, prostate, and bowel.
The FDA has issued a Complete Response Letter for the supplemental New Drug Application (sNDA) of Aggrastat (tirofiban; Medicure) for the expanded indication in patients with ST segment elevation myocardial infarction (STEMI).
After age 80, the bleeding risk with a vitamin K antagonist (VKA) only mildly increases whereas the thrombosis risk in this patient population sharply increases, a study in JAMA Internal Medicine reports.
Patients with heterozygous familial hypercholesterolemia (FH) have a significantly increased risk for coronary heart disease (CHD) and atherosclerotic cardiovascular disease (ASCVD), according to research published online in Circulation.
A new magnetically controlled drug may be able to dissolve a blood clot without negatively affecting the entire network of blood vessels.
Real-World Study Compares Treatment Persistence, Discontinuation of Oral Anticoagulants in Afib Patients
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
Very low target low-density lipoprotein (LDL) cholesterol levels may not benefit all patients with preexisting heart disease, according to a study published online June 20 in JAMA Internal Medicine.
Statin use was not associated with a lower risk of all-cause mortality or time until first hospitalization for an acute exacerbation of chronic obstructive pulmonary disease (COPD), a study published in BMJ Open Respiratory Research has found.